ClinicalTrials.gg
RecruitingNCT06278207FINERODUpdated Nov 6, 2026

An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions

An observational study in Chronic Kidney Disease and Type 2 Diabetes Mellitus, sponsored by Bayer. Recruiting at 4 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Bayer · Observational

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.
Updated Nov 6, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
50,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Renal Insufficiency, Chronic by Bayer — 4 open to participants now, 8 under way, 2 of them phase 3. Renal Insufficiency, Chronic · Bayer.

Planned enrollment
4th of 17
50,000 · median 4,613
Started
2024
with 6 others
Observational
17 of 49
3 open now
Registered
37th of 49
by date

Among the 49 studies in Renal Insufficiency, Chronic by Bayer, this one is the 4th largest by planned enrollment of the 17 observational ones that give a count, is one of 7 that started in 2024, is one of 17 observational ones, and was the 37th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

4 of the 49 studies in Renal Insufficiency, Chronic by Bayer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Renal Insufficiency, Chronic by Bayer, or all of them as a file.
02

Study summary

This is an observational study, in which data from people in Asia and in the United States with chronic kidney disease (CKD) together with type 2 diabetes (T2D) are studied. The participants in this study are already receiving the study treatment finerenone as part of their regular care from their doctors. In observational studies, only observations are made without specified advice or interventions. CKD is a long-term progressive decrease in the kidneys' ability to work properly. In people with T2D, the body does not make enough of a hormone called insulin, or does not use insulin well enough. The resulting high blood sugar levels can cause damage to the kidneys. CKD often occurs together with T2D or as a consequence of T2D. Finerenone works by blocking certain proteins, called mineralocorticoid receptors. By doing this, it may reduce damage to kidneys, heart and blood vessels. Finerenone was recently approved in the US and is now available for doctors to prescribe to people with CKD together with T2D. Consequently, there is a need to collect more information about how finerenone is used, its safety and how well it works under real-world conditions. The main purpose of this study is to collect and describe the characteristics of people with CKD and T2D who are receiving initiate finerenone treatment as prescribed by their doctors. To do this, the researchers will collect general information of the participants such as age or gender and data on kidney function and possible heart problems.

The researchers will also collect data on any other disease or medical condition in the participants and on other medications used while taking finerenone.

The data will come from a network of commercial electronic health records (EHRs) and national claims data in the United States and in Asia. They cover the period from July 1st, 2021 until the latest data cut available for each dataset. Only already available data is collected and studied. There are no required visits or tests in this study.

03

Conditions studied

  • Chronic Kidney Disease
  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with chronic kidney disease and type 2 diabetes who initiate finerenone in secondary data sources (electronic health records (EHR) and claims data) in the United States and in Asia.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A minimum of 12 months of continuous enrolment in the databases with medical and pharmacy coverage measured as continuously receiving medical care from health providers contributing to the EHR or claims system, depending on the database used
  • No recorded prescription for finerenone in the 12 months prior to the index date
  • Age of 18 years or older as of the index date
  • Evidence of T2D at any point before (and including) the index date.
  • CKD stages 2-4 related to eligibility will be defined according to the presence of the following criteria at any point before (and including) the index date:

    • A diagnosis code indicating CKD stage 2, 3, 4 or stage unspecified
    • two UACR tests results ≥ 30 mg/g separated by at least 90 days and by not more than 540 days
    • two different test results ≥ 15 mL/min/1.73 m2 AND \< 60 mL/min/1.73 m2 separated by at least 90 days and by not more than 540 days

Exclusion criteria

Exclusion Criteria:

- Kidney failure defined as follows:

  • Two different test results \< 15 mL/min/1.73 m2 separated by at least 90 days and by not more than 540 days;
  • Dependence on dialysis (at least 3 sessions over at least 90 days during the baseline period);
  • A diagnosis code indicating kidney failure or CKD stage 5; Kidney transplant
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
50,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Adult patients with CKD and T2D who initiate finerenone

    The data sources used include a network of commercial electronic health records (EHRs) and national claims data in Asia and in the United States.

    Drug: Finerenone (BAY 94-8862)

Interventions

06

What researchers measure

Primary outcomes

  1. Participants' characteristics at baseline in a cohort of participants with CKD and T2D who initiate finerenone.

    Sociodemographic characteristics such as age, sex, race and socio-economic status.

    Time frame: 12 months before first prescription/dispensation of finerenone (index date)

  2. Participants' comorbidities at baseline in a cohort of participants with CKD and T2D who initiate finerenone.

    Including heart diseases, lipid diseases, liver disease, hospitalization for acute kidney injury, dementia, body mass index, smoking status, alcohol abuse, and other comorbidities measured using comorbidities indexes (such as the Charlson comorbidity index)

    Time frame: 12 months before first prescription/dispensation of finerenone (index date)

  3. Participants' comedications at baseline in a cohort of participants with CKD and T2D who initiate finerenone.

    In subcohorts of participants in co-medication between finerenone and other hypertensive and diabetic medications (SGLT2i, RAASi, GLP-1 RA, etc.), characterized by CKD stage, including a 15-25 ml/min/1.73 m2 eGFR subgroup.

    Time frame: 12 months before first prescription/dispensation of finerenone (index date)

Secondary outcomes

  1. Proportion of finerenone initiators with and without UACR measurements at baseline

    UACR=Urinary Albumin-to-Creatinine Ratio

    Time frame: From first prescription/dispensation of finerenone (index date) until 12 months after index date

  2. Average UACR in the subcohort with UACR measurements

    Time frame: From first prescription/dispensation of finerenone (index date) until 12 months after index date

  3. Incidence rate of kidney failure in participants with CKD and T2D that initiate finerenone.

    Any of the following: ≥ 2 outpatient eGFR measurements of \< 15 mL/min/1.73 m2 separated by at least 90 days; Record of dependence on dialysis (at least 3 sessions over at least 90 days); Diagnosis records of kidney failure or CKD stage 5; Record of kidney transplant

    Time frame: From first prescription/dispensation of finerenone (index date) until end of follow-up (death, disenrollment, development of either kidney failure or kidney cancer, or by the last available date in the corresponding database) up to 150 months

  4. Incidence rate of a composite cardiovascular outcome in participants with CKD and T2D that initiate finerenone.

    Acute myocardial infarction, identified as an inpatient hospital diagnosis of fatal or non-fatal acute myocardial infarction. Congestive heart failure, identified as an impatient hospital or emergency department diagnosis of heart failure and stratified by new-onset or recurrent heart failure.

    Time frame: From first prescription/dispensation of finerenone (index date) until end of follow-up (death, disenrollment, development of either kidney failure or kidney cancer, or by the last available date in the corresponding database) up to 150 months

  5. Drug utilization patterns in a cohort of participants with CKD and T2D that initiate finerenone.

    Depending on the database used, this includes incidence of drug use, initiation of treatment measured by drug prescription, drug dispensation, or a combination of both depending on data availability, dosing regimen, treatment persistence and non-persistence, and implementation measured as the proportion of days covered.

    Time frame: From first prescription/dispensation of finerenone (index date) until end of follow-up (death, disenrollment, development of either kidney failure or kidney cancer, or by the last available date in the corresponding database) up to 150 months

  6. Number of participants who initiate finerenone at a 10 mg dose daily

    Time frame: At day 0 (first prescription/dispensation of finerenone)

  7. Proportion of participants who continue the original 10 mg dose daily at the 1, 3, 6, and 12 months mark

    Time frame: From first prescription/dispensation of finerenone (index date) until 12 months after index date

  8. Proportion of participants who up-titrate from 10 mg daily dose to a 20 mg dose daily at the 1, 3, 6, and 12 months mark

    Time frame: From first prescription/dispensation of finerenone (index date) until 12 months after index date

  9. Number of participants who initiate finerenone at a 20 mg dose daily

    Time frame: At day 0 (first prescription/dispensation of finerenone)

  10. Proportion of participants who continue the original 20 mg dose daily at the 1, 3, 6, and 12 months mark

    Time frame: From first prescription/dispensation of finerenone (index date) until 12 months after index date

  11. Proportion of participants who down-titrate from 20 mg daily dose to a 10 mg dose daily at the 1, 3, 6, and 12 months mark

    Time frame: From first prescription/dispensation of finerenone (index date) until 12 months after index date

  12. Incidence rate of hospitalization for heart failure in participants with CKD and T2D that initiate finerenone.

    Congestive heart failure, identified as an impatient hospital or emergency department diagnosis of heart failure and stratified by new-onset or recurrent heart failure.

    Time frame: From first prescription/dispensation of finerenone (index date) until end of follow-up (death, disenrollment, development of either kidney failure or kidney cancer, or by the last available date in the corresponding database) up to 150 months

  13. Incidence rate of atrial fibrillation or flutter in participants with CKD and T2D that initiate finerenone.

    Time frame: From first prescription/dispensation of finerenone (index date) until end of follow-up (death, disenrollment, development of either kidney failure or kidney cancer, or by the last available date in the corresponding database) up to 150 months

  14. Incidence rate of hyperkalemia in participants with CKD and T2D that initiate finerenone.

    Time frame: From first prescription/dispensation of finerenone (index date) until end of follow-up (death, disenrollment, development of either kidney failure or kidney cancer, or by the last available date in the corresponding database) up to 150 months

  15. Incidence rate of hospitalization associated with hyperkalemia in participants with CKD and T2D that initiate finerenone.

    Time frame: From first prescription/dispensation of finerenone (index date) until end of follow-up (death, disenrollment, development of either kidney failure or kidney cancer, or by the last available date in the corresponding database) up to 150 months

07

Study locations

1 of 4 sites recruiting
  • Many Locations
    Many Locations, New Jersey 07981, United States
    Completed

    Not enrolling at this site.

  • Bayer
    Berlin, 13353, Germany
    Recruiting
  • Many Locations
    Many Locations, Japan
    Completed

    Not enrolling at this site.

  • Many Locations
    Many Locations, Taiwan
    Completed

    Not enrolling at this site.

08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2024 (actual). Primary completion is estimated for Sep 2027, 40 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Sep 2026 → Sep 2027 and completion Sep 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2024
First posted
Feb 26, 2024
StartActual
May 15, 2024
Primary completionEst.
Sep 30, 2027was Sep 2026
CompletionEst.
Sep 30, 2027was Sep 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 3 sites removed
Show 3 added (1 United States, 1 Japan, 1 Taiwan)
  • Many Locations · Many Locations, United States
  • Many Locations · Many Locations, Japan
  • Many Locations · Many Locations, Taiwan
Show 3 removed
  • Many Locations · Multiple Locations, United States
  • Many Locations · Multiple Locations, Japan
  • Many Locations · Multiple Locations, Taiwan
Nov 6, 2026
Primary completion
Sep 30, 2026→Sep 30, 2027
Nov 6, 2026
Study completion
Sep 30, 2026→Sep 30, 2027
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    3 sites added, 3 sites removed
    Show 3 added (1 United States, 1 Japan, 1 Taiwan)
    • Many Locations · Many Locations, United States
    • Many Locations · Many Locations, Japan
    • Many Locations · Many Locations, Taiwan
    Show 3 removed
    • Many Locations · Multiple Locations, United States
    • Many Locations · Multiple Locations, Japan
    • Many Locations · Multiple Locations, Taiwan
    Primary completion Sep 30, 2026→Sep 30, 2027
    Study completion Sep 30, 2026→Sep 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06278207
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Feb 26, 2024
Start date
May 15, 2024
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Bayer Clinical Trials Contact
Contact
clinical-trials-contact@bayer.com
(+)1-888-84 22937

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion